EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis

Xian Li, Xueyan Wang, Qintai Yang, Jianjun Chen, Hao Tian, Meiping Lu, Tingting Ma, Yana Zhang, Yue Zhou, Jiao Xia, Lei Cheng, Yuan Zhang und 1 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2024.12.035 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Xian Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Department of Otolaryngology Head and Neck Surgery, Beij…. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Mometasone Furoate, Rhinitis, Allergic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Moderate to severe persistent allergic rhinitis (AR) poses a substantial socioeconomic burden. OBJECTIVES: We aimed to establish the superiority of bencycloquidium bromide (BCQB) nasal spray and BCQB combined with mometasone furoate nasal spray (MFNS) over MFNS alone in adults with moderate to severe persistent AR. METHODS: In this multicenter, randomized, controlled clinical trial (NCT05038202), adults with moderate to severe persistent AR were randomly assigned to receive BCQB, MFNS, or a combination treatment for 4-week periods. Mean changes from baseline in the daily reflective runny nose, nasal congestion, sneezing, nasal itching scores, total nasal symptom score (TNSS) and Rhinoconjunctivitis Quality of Life Questionnaire scores were recorded. We also assessed the exploratory end points and adverse events. RESULTS: Bencycloquidium bromide led to a significant improvement in the mean change from baseline in daily reflective runny nose during the 4-week treatment, compared with MFNS (least-squares mean difference, -0.27; 95% CI, -0.44 to -0.09; P = .004). The BCQB combined with MFNS significantly improved runny nose, nasal congestion, sneezing, TNSS, and Rhinoconjunctivitis Quality of Life Questionnaire scores compared with MFNS alone, except for nasal itching. Bencycloquidium bromide significantly decreased the percent change in eosinophilic cationic protein, eotaxin, vasoactive intestinal peptide, and IL-6 levels. Treatment-emergent adverse events were similar among the three groups. CONCLUSIONS: Bencycloquidium bromide was superior to MFNS in reducing daily runny nose symptoms. The combination of BCQB and MFNS was superior to MFNS alone in alleviating TNSS in patients with moderate to severe persistent AR with a predominant symptom of runny nose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsMometasone FuroateRhinitis, AllergicAdultFemaleHumansMaleMiddle AgedYoung AdultDrug Therapy, CombinationNasal SpraysQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Allergic rhinitisCholinergic antagonistsClinical trialModerate to severe

Substanzen

Anti-Allergic AgentsMometasone FuroateNasal Sprays

Autor:innen und Institutionen

  • Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beij…
  • Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Department of Allergy, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Chin…
  • Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Otorhinolaryngology Head and Neck Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Otorhinolaryngology and Clinical Allergy Center, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Zitieren

APA

Li, X., Wang, X., Yang, Q., Chen, J., Tian, H., Lu, M., Ma, T., Zhang, Y., Zhou, Y., Xia, J., Cheng, L., Zhang, Y., & Zhang, L. (2025). A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.12.035

Vancouver

Li X, Wang X, Yang Q, Chen J, Tian H, Lu M, et al. A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2024.12.035

BibTeX
@article{Li2025,
  author = {Li, Xian and Wang, Xueyan and Yang, Qintai and Chen, Jianjun and Tian, Hao and Lu, Meiping and Ma, Tingting and Zhang, Yana and Zhou, Yue and Xia, Jiao and Cheng, Lei and Zhang, Yuan and Zhang, Luo},
  title = {A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2024.12.035}
}
Kostenlos starten →